Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone XR in Mild to Moderate Alzheimer's Disease
NCT00334568Phase 2Terminated
- Sponsor
- GSK
- Start
- Dec 2004
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rosiglitazone in Alzheimer's disease (AD), sponsored by GSK. Started Dec 2004; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00334568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334568.